JP2016531913A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531913A5 JP2016531913A5 JP2016537782A JP2016537782A JP2016531913A5 JP 2016531913 A5 JP2016531913 A5 JP 2016531913A5 JP 2016537782 A JP2016537782 A JP 2016537782A JP 2016537782 A JP2016537782 A JP 2016537782A JP 2016531913 A5 JP2016531913 A5 JP 2016531913A5
- Authority
- JP
- Japan
- Prior art keywords
- ketamine
- tablet composition
- gum
- composition according
- naket
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 19
- 229960003299 ketamine Drugs 0.000 claims 19
- 239000007916 tablet composition Substances 0.000 claims 16
- 238000000034 method Methods 0.000 claims 6
- 239000002356 single layer Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 125000000129 anionic group Chemical group 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 1
- BEQZHFIKTBVCAU-UHFFFAOYSA-N 2-amino-2-(2-chlorophenyl)-1-cyclohexanone Chemical compound C=1C=CC=C(Cl)C=1C1(N)CCCCC1=O BEQZHFIKTBVCAU-UHFFFAOYSA-N 0.000 claims 1
- 244000215068 Acacia senegal Species 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 229920002101 Chitin Polymers 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 229920002907 Guar gum Polymers 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- 229920000569 Gum karaya Polymers 0.000 claims 1
- 229920000161 Locust bean gum Polymers 0.000 claims 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 241000934878 Sterculia Species 0.000 claims 1
- 229920001615 Tragacanth Polymers 0.000 claims 1
- 229910021536 Zeolite Inorganic materials 0.000 claims 1
- 235000010489 acacia gum Nutrition 0.000 claims 1
- 239000000205 acacia gum Substances 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- 239000000305 astragalus gummifer gum Substances 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 229920001525 carrageenan Polymers 0.000 claims 1
- 229940113118 carrageenan Drugs 0.000 claims 1
- 239000003729 cation exchange resin Substances 0.000 claims 1
- 239000004927 clay Substances 0.000 claims 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 claims 1
- 235000010417 guar gum Nutrition 0.000 claims 1
- 239000000665 guar gum Substances 0.000 claims 1
- 229960002154 guar gum Drugs 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 235000010494 karaya gum Nutrition 0.000 claims 1
- 239000000231 karaya gum Substances 0.000 claims 1
- 229940039371 karaya gum Drugs 0.000 claims 1
- 235000010420 locust bean gum Nutrition 0.000 claims 1
- 239000000711 locust bean gum Substances 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 230000001508 neuroinhibitory effect Effects 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 239000007935 oral tablet Substances 0.000 claims 1
- 229940096978 oral tablet Drugs 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 229960000292 pectin Drugs 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 239000004584 polyacrylic acid Substances 0.000 claims 1
- 239000004633 polyglycolic acid Substances 0.000 claims 1
- 239000004626 polylactic acid Substances 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 229920002994 synthetic fiber Polymers 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
- 239000010457 zeolite Substances 0.000 claims 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361869884P | 2013-08-26 | 2013-08-26 | |
| US61/869,884 | 2013-08-26 | ||
| US201462015513P | 2014-06-22 | 2014-06-22 | |
| US62/015,513 | 2014-06-22 | ||
| PCT/US2014/052786 WO2015031410A1 (en) | 2013-08-26 | 2014-08-26 | Single-layer oral dose of neuro-attenuating ketamine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020016717A Division JP2020079273A (ja) | 2013-08-26 | 2020-02-04 | 神経抑制性ケタミンの単層による経口投与 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016531913A JP2016531913A (ja) | 2016-10-13 |
| JP2016531913A5 true JP2016531913A5 (enExample) | 2017-10-05 |
Family
ID=52587281
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016537782A Pending JP2016531913A (ja) | 2013-08-26 | 2014-08-26 | 神経抑制性ケタミンの単層による経口投与 |
| JP2020016717A Pending JP2020079273A (ja) | 2013-08-26 | 2020-02-04 | 神経抑制性ケタミンの単層による経口投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020016717A Pending JP2020079273A (ja) | 2013-08-26 | 2020-02-04 | 神経抑制性ケタミンの単層による経口投与 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US9913803B2 (enExample) |
| EP (2) | EP3960162A1 (enExample) |
| JP (2) | JP2016531913A (enExample) |
| CA (1) | CA2922507C (enExample) |
| WO (1) | WO2015031410A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20200404A1 (es) | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina |
| EP3960162A1 (en) | 2013-08-26 | 2022-03-02 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| WO2015065547A1 (en) | 2013-10-31 | 2015-05-07 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| EP3131533B1 (en) * | 2014-04-17 | 2019-06-05 | Develco Pharma Schweiz AG | Oral dosage form of ketamine |
| KR20170054470A (ko) | 2014-09-15 | 2017-05-17 | 얀센 파마슈티카 엔.브이. | VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법 |
| EP3215147B1 (en) | 2014-11-04 | 2024-02-28 | ACADIA Pharmaceuticals Inc. | Neuro-attenuating norketamine compounds and methods |
| EP3229788A4 (en) | 2014-12-08 | 2018-06-13 | Cima Labs Inc. | Immediate release abuse-deterrent granulated dosage forms |
| AU2016288188B2 (en) | 2015-06-27 | 2021-08-05 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
| WO2018191482A2 (en) * | 2017-04-13 | 2018-10-18 | Ovid Therapeutics Inc. | Methods of treating developmental encephalopathies |
| WO2018234568A2 (en) * | 2017-06-23 | 2018-12-27 | Develco Pharma Schweiz Ag | Hydroxynorketamine for the use in the treatment of depression |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| US10441544B2 (en) | 2017-10-10 | 2019-10-15 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| US12090123B2 (en) | 2017-10-10 | 2024-09-17 | Douglas Pharmaceuticals Ltd. | Extended release pharmaceutical formulation |
| US11471415B2 (en) | 2017-10-10 | 2022-10-18 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation and methods of treatment |
| CN111630026A (zh) * | 2017-10-10 | 2020-09-04 | 道格拉斯制药有限公司 | 缓释药物制剂和治疗方法 |
| US10869838B2 (en) | 2017-10-10 | 2020-12-22 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| IL275482B1 (en) | 2017-12-22 | 2025-03-01 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| EP3505157B1 (en) | 2017-12-29 | 2021-12-08 | Celon Pharma S.A. | Dry powder ketamine composition for pulmonary administration in treatment-resistant depression |
| EP3813807A1 (en) | 2018-06-27 | 2021-05-05 | Clexio Biosciences Ltd. | Method of treating major depressive disorder |
| CN112702995A (zh) | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾氯胺酮的治疗方案 |
| US12364672B2 (en) | 2018-10-11 | 2025-07-22 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| WO2020178653A1 (en) | 2019-03-05 | 2020-09-10 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
| JP7381597B2 (ja) * | 2019-03-25 | 2023-11-15 | ダグラス ファーマシューティカルズ エルティーディー． | 持続放出性の医薬製剤 |
| US20220062200A1 (en) | 2019-05-07 | 2022-03-03 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| US11324707B2 (en) | 2019-05-07 | 2022-05-10 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
| WO2021070120A1 (en) | 2019-10-11 | 2021-04-15 | Pike Therapeutics, Inc., 1219014 B.C. Ltd. | Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー． | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| IL293506A (en) | 2019-12-30 | 2022-08-01 | Clexio Biosciences Ltd | Dosage regime with esketamine for treating major depressive disorder |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204116A (en) * | 1991-05-01 | 1993-04-20 | Alza Corporation | Dosage form providing immediate therapy followed by prolonged therapy |
| AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
| EP1103256A1 (de) | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom |
| US20020160043A1 (en) * | 2001-02-27 | 2002-10-31 | Dennis Coleman | Compositions and method of manufacture for oral dissolvable dosage forms |
| UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
| US6855735B2 (en) * | 2002-03-20 | 2005-02-15 | Temple University Of The Commonwealth System Of Higher Education | Ketamine treatment of restless legs syndrome |
| RU2004139075A (ru) * | 2002-06-10 | 2005-06-27 | Уайт (Us) | Новые формиат 0-десметилвенлафаксина |
| US20080027119A1 (en) * | 2002-07-31 | 2008-01-31 | Lippa Arnold S | Methods and compositions employing bicifadine for the treatment of acute pain, chronic pain, and symptoms of neuropathic disorders |
| WO2006053012A2 (en) * | 2004-11-10 | 2006-05-18 | Trinity Laboratories, Inc. | Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria |
| WO2008118785A2 (en) * | 2007-03-23 | 2008-10-02 | Tikvah Therapeutics | Methods for treating depression using immediate-impact treatments and d-cycloserine |
| CA2685344A1 (en) | 2007-04-26 | 2008-11-06 | Auspex Pharmaceuticals, Inc. | Deuterium labelled ketamine |
| WO2009131794A1 (en) | 2008-03-27 | 2009-10-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
| WO2013003669A2 (en) | 2011-06-30 | 2013-01-03 | University Of South Florida | Compositions, methods of use, and methods of treatment |
| WO2014020155A1 (en) | 2012-08-02 | 2014-02-06 | Clinpharm Reform Gmbh | Oral transmucosal adminstration forms of s-ketamine |
| EP3960162A1 (en) * | 2013-08-26 | 2022-03-02 | Amorsa Therapeutics, Inc. | Single-layer oral dose of neuro-attenuating ketamine |
| JP6374965B2 (ja) | 2013-09-23 | 2018-08-15 | コンヴィオン オサケユキチュアＣｏｎｖｉｏｎ Ｏｙ | 高温電池システムのための再循環装置及び方法 |
-
2014
- 2014-08-26 EP EP21181816.6A patent/EP3960162A1/en not_active Withdrawn
- 2014-08-26 JP JP2016537782A patent/JP2016531913A/ja active Pending
- 2014-08-26 EP EP14840272.0A patent/EP3035918B1/en active Active
- 2014-08-26 CA CA2922507A patent/CA2922507C/en active Active
- 2014-08-26 WO PCT/US2014/052786 patent/WO2015031410A1/en not_active Ceased
- 2014-08-26 US US14/914,416 patent/US9913803B2/en active Active
-
2018
- 2018-01-31 US US15/885,231 patent/US10653629B2/en active Active
-
2020
- 2020-02-04 JP JP2020016717A patent/JP2020079273A/ja active Pending
- 2020-05-06 US US16/868,444 patent/US11554100B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016531913A5 (enExample) | ||
| Filous et al. | Targeting astrocytes in CNS injury and disease: A translational research approach | |
| CY1123460T1 (el) | Ενωσεις και μεθοδοι για τη θεραπεια μιας επιληπτικης διαταραχης | |
| PH12013500215B1 (en) | Corticosteroids for the treatment of joint pain | |
| WO2017132432A8 (en) | Benzimidazole derivatives as modulators of ror-gamma | |
| RU2020127610A (ru) | Нейроактивные стероиды, композиции и способы их применения | |
| WO2017087608A8 (en) | Modulators of ror-gamma | |
| EP2911695C0 (en) | COMPOSITIONS AND METHODS FOR TREATING PARKINSON'S DISEASE BY SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC TYPES OF NEURONS | |
| MX2018002906A (es) | Metodos de tratamiento de trastornos del desarrollo con pipradrol. | |
| JP2013535505A5 (enExample) | ||
| JP2012046524A5 (enExample) | ||
| HRP20250250T1 (hr) | Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji | |
| WO2013101897A3 (en) | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid | |
| WO2015118537A3 (en) | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions | |
| NZ700374A (en) | New therapeutic approaches for treating parkinson’s disease | |
| EA032951B1 (ru) | Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения | |
| MX370898B (es) | Agente terapéutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor. | |
| JP2017507142A5 (enExample) | ||
| MX2013012206A (es) | Metodo para producir substancias con gas sobresaturado,dispositivo de suministro transdermico de las mismas, y usos de las mismas. | |
| JP2016515550A5 (enExample) | ||
| JP2017061488A5 (enExample) | ||
| JP2017531042A5 (enExample) | ||
| JP2015512948A5 (enExample) | ||
| WO2014011949A3 (en) | Neuroprotective cb2 receptor agonists | |
| JP2013541582A5 (enExample) |